Tenofovir may reduce risk of liver cancer in patients with HBV infection
the ONA take:
A new study published online ahead of print in the journal Cancer has shown that long-term therapy with tenofovir disoproxil fumarate (TDF) was associated with a decreased incidence of hepatocellular carcinoma among patients with chronic hepatitis B virus (HBV) infection without cirrhosis.
According to the American Cancer Society, there will be nearly 36,000 new cases of liver cancer diagnosed in the 2015 and about 24,550 people will die from the disease.
For the study, researchers analyzed data from the pivotal TDF registration studies that followed patients for 384 weeks. Of the 634 patients included for analysis, 152 had cirrhosis and 482 did not. During the study period, 14 patients developed hepatocellular carcinoma.
Results showed that the incidence of hepatocellular carcinoma was significantly lower than predicted among patients without cirrhosis.
TDF is an oral antiviral medication used to treat HIV infection in combination with other drugs and chronic HBV infection.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|